Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus
Objective Both genetic and epigenetic factors play an important role in the pathogenesis of lupus. The aim of this study was to examine methyl‐CpG–binding protein 2 gene (MECP2) polymorphisms in a large cohort of patients with lupus and control subjects, and to determine the functional consequences...
Saved in:
Published in | Arthritis and rheumatism Vol. 60; no. 4; pp. 1076 - 1084 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.04.2009
Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objective
Both genetic and epigenetic factors play an important role in the pathogenesis of lupus. The aim of this study was to examine methyl‐CpG–binding protein 2 gene (MECP2) polymorphisms in a large cohort of patients with lupus and control subjects, and to determine the functional consequences of the lupus‐associated MECP2 haplotype.
Methods
We genotyped 18 single‐nucleotide polymorphisms within MECP2, located on chromosome Xq28, in a large cohort of patients with lupus and control subjects of European descent. We studied the functional effects of the lupus‐associated MECP2 haplotype by determining gene expression profiles in B cell lines in female lupus patients with and those without the lupus‐associated MECP2 risk haplotype.
Results
We confirmed, replicated, and extended the genetic association between lupus and genetic markers within MECP2 in a large independent cohort of lupus patients and control subjects of European descent (odds ratio 1.35, P = 6.65 × 10−11). MECP2 is a dichotomous transcription regulator that either activates or represses gene expression. We identified 128 genes that are differentially expressed in lupus patients with the disease‐associated MECP2 haplotype; most (∼81%) were up‐regulated. Genes that were up‐regulated had significantly more CpG islands in their promoter regions compared with genes that were down‐regulated. Gene ontology analysis using the differentially expressed genes revealed significant association with epigenetic regulatory mechanisms, suggesting that these genes are targets for MECP2 regulation in B cells. Furthermore, at least 13 of the 104 up‐regulated genes are regulated by interferon. The disease‐risk MECP2 haplotype was associated with increased expression of the MECP2 transcription coactivator CREB1 and decreased expression of the corepressor histone deacetylase 1.
Conclusion
Polymorphism in the MECP2 locus is associated with lupus and, at least in part, contributes to the interferon signature observed in lupus patients. |
---|---|
AbstractList | OBJECTIVE: Both genetic and epigenetic factors play an important role in the pathogenesis of lupus. The aim of this study was to examine methyl-CpG-binding protein 2 gene (MECP2) polymorphisms in a large cohort of patients with lupus and control subjects, and to determine the functional consequences of the lupus-associated MECP2 haplotype. METHODS: We genotyped 18 single-nucleotide polymorphisms within MECP2, located on chromosome Xq28, in a large cohort of patients with lupus and control subjects of European descent. We studied the functional effects of the lupus-associated MECP2 haplotype by determining gene expression profiles in B cell lines in female lupus patients with and those without the lupus-associated MECP2 risk haplotype. RESULTS: We confirmed, replicated, and extended the genetic association between lupus and genetic markers within MECP2 in a large independent cohort of lupus patients and control subjects of European descent (odds ratio 1.35, P = 6.65 x 10(-11)). MECP2 is a dichotomous transcription regulator that either activates or represses gene expression. We identified 128 genes that are differentially expressed in lupus patients with the disease-associated MECP2 haplotype; most ( approximately 81%) were up-regulated. Genes that were up-regulated had significantly more CpG islands in their promoter regions compared with genes that were down-regulated. Gene ontology analysis using the differentially expressed genes revealed significant association with epigenetic regulatory mechanisms, suggesting that these genes are targets for MECP2 regulation in B cells. Furthermore, at least 13 of the 104 up-regulated genes are regulated by interferon. The disease-risk MECP2 haplotype was associated with increased expression of the MECP2 transcription coactivator CREB1 and decreased expression of the corepressor histone deacetylase 1. CONCLUSION: Polymorphism in the MECP2 locus is associated with lupus and, at least in part, contributes to the interferon signature observed in lupus patients. Objective Both genetic and epigenetic factors play an important role in the pathogenesis of lupus. The aim of this study was to examine methyl‐CpG–binding protein 2 gene (MECP2) polymorphisms in a large cohort of patients with lupus and control subjects, and to determine the functional consequences of the lupus‐associated MECP2 haplotype. Methods We genotyped 18 single‐nucleotide polymorphisms within MECP2, located on chromosome Xq28, in a large cohort of patients with lupus and control subjects of European descent. We studied the functional effects of the lupus‐associated MECP2 haplotype by determining gene expression profiles in B cell lines in female lupus patients with and those without the lupus‐associated MECP2 risk haplotype. Results We confirmed, replicated, and extended the genetic association between lupus and genetic markers within MECP2 in a large independent cohort of lupus patients and control subjects of European descent (odds ratio 1.35, P = 6.65 × 10−11). MECP2 is a dichotomous transcription regulator that either activates or represses gene expression. We identified 128 genes that are differentially expressed in lupus patients with the disease‐associated MECP2 haplotype; most (∼81%) were up‐regulated. Genes that were up‐regulated had significantly more CpG islands in their promoter regions compared with genes that were down‐regulated. Gene ontology analysis using the differentially expressed genes revealed significant association with epigenetic regulatory mechanisms, suggesting that these genes are targets for MECP2 regulation in B cells. Furthermore, at least 13 of the 104 up‐regulated genes are regulated by interferon. The disease‐risk MECP2 haplotype was associated with increased expression of the MECP2 transcription coactivator CREB1 and decreased expression of the corepressor histone deacetylase 1. Conclusion Polymorphism in the MECP2 locus is associated with lupus and, at least in part, contributes to the interferon signature observed in lupus patients. Both genetic and epigenetic factors play an important role in the pathogenesis of lupus. The aim of this study was to examine methyl-CpG-binding protein 2 gene (MECP2) polymorphisms in a large cohort of patients with lupus and control subjects, and to determine the functional consequences of the lupus-associated MECP2 haplotype.OBJECTIVEBoth genetic and epigenetic factors play an important role in the pathogenesis of lupus. The aim of this study was to examine methyl-CpG-binding protein 2 gene (MECP2) polymorphisms in a large cohort of patients with lupus and control subjects, and to determine the functional consequences of the lupus-associated MECP2 haplotype.We genotyped 18 single-nucleotide polymorphisms within MECP2, located on chromosome Xq28, in a large cohort of patients with lupus and control subjects of European descent. We studied the functional effects of the lupus-associated MECP2 haplotype by determining gene expression profiles in B cell lines in female lupus patients with and those without the lupus-associated MECP2 risk haplotype.METHODSWe genotyped 18 single-nucleotide polymorphisms within MECP2, located on chromosome Xq28, in a large cohort of patients with lupus and control subjects of European descent. We studied the functional effects of the lupus-associated MECP2 haplotype by determining gene expression profiles in B cell lines in female lupus patients with and those without the lupus-associated MECP2 risk haplotype.We confirmed, replicated, and extended the genetic association between lupus and genetic markers within MECP2 in a large independent cohort of lupus patients and control subjects of European descent (odds ratio 1.35, P = 6.65 x 10(-11)). MECP2 is a dichotomous transcription regulator that either activates or represses gene expression. We identified 128 genes that are differentially expressed in lupus patients with the disease-associated MECP2 haplotype; most ( approximately 81%) were up-regulated. Genes that were up-regulated had significantly more CpG islands in their promoter regions compared with genes that were down-regulated. Gene ontology analysis using the differentially expressed genes revealed significant association with epigenetic regulatory mechanisms, suggesting that these genes are targets for MECP2 regulation in B cells. Furthermore, at least 13 of the 104 up-regulated genes are regulated by interferon. The disease-risk MECP2 haplotype was associated with increased expression of the MECP2 transcription coactivator CREB1 and decreased expression of the corepressor histone deacetylase 1.RESULTSWe confirmed, replicated, and extended the genetic association between lupus and genetic markers within MECP2 in a large independent cohort of lupus patients and control subjects of European descent (odds ratio 1.35, P = 6.65 x 10(-11)). MECP2 is a dichotomous transcription regulator that either activates or represses gene expression. We identified 128 genes that are differentially expressed in lupus patients with the disease-associated MECP2 haplotype; most ( approximately 81%) were up-regulated. Genes that were up-regulated had significantly more CpG islands in their promoter regions compared with genes that were down-regulated. Gene ontology analysis using the differentially expressed genes revealed significant association with epigenetic regulatory mechanisms, suggesting that these genes are targets for MECP2 regulation in B cells. Furthermore, at least 13 of the 104 up-regulated genes are regulated by interferon. The disease-risk MECP2 haplotype was associated with increased expression of the MECP2 transcription coactivator CREB1 and decreased expression of the corepressor histone deacetylase 1.Polymorphism in the MECP2 locus is associated with lupus and, at least in part, contributes to the interferon signature observed in lupus patients.CONCLUSIONPolymorphism in the MECP2 locus is associated with lupus and, at least in part, contributes to the interferon signature observed in lupus patients. Both genetic and epigenetic factors play an important role in the pathogenesis of lupus. The aim of this study was to examine methyl-CpG-binding protein 2 gene (MECP2) polymorphisms in a large cohort of patients with lupus and control subjects, and to determine the functional consequences of the lupus-associated MECP2 haplotype. We genotyped 18 single-nucleotide polymorphisms within MECP2, located on chromosome Xq28, in a large cohort of patients with lupus and control subjects of European descent. We studied the functional effects of the lupus-associated MECP2 haplotype by determining gene expression profiles in B cell lines in female lupus patients with and those without the lupus-associated MECP2 risk haplotype. We confirmed, replicated, and extended the genetic association between lupus and genetic markers within MECP2 in a large independent cohort of lupus patients and control subjects of European descent (odds ratio 1.35, P = 6.65 x 10(-11)). MECP2 is a dichotomous transcription regulator that either activates or represses gene expression. We identified 128 genes that are differentially expressed in lupus patients with the disease-associated MECP2 haplotype; most ( approximately 81%) were up-regulated. Genes that were up-regulated had significantly more CpG islands in their promoter regions compared with genes that were down-regulated. Gene ontology analysis using the differentially expressed genes revealed significant association with epigenetic regulatory mechanisms, suggesting that these genes are targets for MECP2 regulation in B cells. Furthermore, at least 13 of the 104 up-regulated genes are regulated by interferon. The disease-risk MECP2 haplotype was associated with increased expression of the MECP2 transcription coactivator CREB1 and decreased expression of the corepressor histone deacetylase 1. Polymorphism in the MECP2 locus is associated with lupus and, at least in part, contributes to the interferon signature observed in lupus patients. |
Author | Edberg, Jeffrey C. Harley, John B. Petri, Michelle Reveille, John D. Alarcón, Graciela S. Alarcón‐Riquelme, Marta E. Frank, Mark Barton James, Judith A. Gilkeson, Gary S. Ramsey‐Goldman, Rosalind Merrill, Joan Wren, Jonathan D. Gaffney, Patrick M. Tang, Yuhong Jeffries, Matlock Vyse, Timothy J. Kaufman, Kenneth M. Kimberly, Robert P. Webb, Ryan Vilá, Luis M. Kelly, Jennifer A. Moser, Kathy L. Sawalha, Amr H. |
Author_xml | – sequence: 1 givenname: Ryan surname: Webb fullname: Webb, Ryan – sequence: 2 givenname: Jonathan D. surname: Wren fullname: Wren, Jonathan D. – sequence: 3 givenname: Matlock surname: Jeffries fullname: Jeffries, Matlock – sequence: 4 givenname: Jennifer A. surname: Kelly fullname: Kelly, Jennifer A. – sequence: 5 givenname: Kenneth M. surname: Kaufman fullname: Kaufman, Kenneth M. – sequence: 6 givenname: Yuhong surname: Tang fullname: Tang, Yuhong – sequence: 7 givenname: Mark Barton surname: Frank fullname: Frank, Mark Barton – sequence: 8 givenname: Joan surname: Merrill fullname: Merrill, Joan – sequence: 9 givenname: Robert P. surname: Kimberly fullname: Kimberly, Robert P. – sequence: 10 givenname: Jeffrey C. surname: Edberg fullname: Edberg, Jeffrey C. – sequence: 11 givenname: Rosalind surname: Ramsey‐Goldman fullname: Ramsey‐Goldman, Rosalind – sequence: 12 givenname: Michelle surname: Petri fullname: Petri, Michelle – sequence: 13 givenname: John D. surname: Reveille fullname: Reveille, John D. – sequence: 14 givenname: Graciela S. surname: Alarcón fullname: Alarcón, Graciela S. – sequence: 15 givenname: Luis M. surname: Vilá fullname: Vilá, Luis M. – sequence: 16 givenname: Marta E. surname: Alarcón‐Riquelme fullname: Alarcón‐Riquelme, Marta E. – sequence: 17 givenname: Judith A. surname: James fullname: James, Judith A. – sequence: 18 givenname: Timothy J. surname: Vyse fullname: Vyse, Timothy J. – sequence: 19 givenname: Kathy L. surname: Moser fullname: Moser, Kathy L. – sequence: 20 givenname: Patrick M. surname: Gaffney fullname: Gaffney, Patrick M. – sequence: 21 givenname: Gary S. surname: Gilkeson fullname: Gilkeson, Gary S. – sequence: 22 givenname: John B. surname: Harley fullname: Harley, John B. – sequence: 23 givenname: Amr H. surname: Sawalha fullname: Sawalha, Amr H. email: amr‐sawalha@omrf.ouhsc.edu |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21299701$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19333917$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-102307$$DView record from Swedish Publication Index |
BookMark | eNp1kt1uEzEQhS1URNPABS-AfAMSUtPa3l9fRqH8SEUgVHprzTqzqWHj3Xq8Cnk1ng6nSXOB4Mqy5jtnRnPmjJ343iNjL6W4kEKoSwjxQuVZKZ6wiSyUngmZyRM2EULks6zQ8pSdEf1IX5UV2TN2KnWWZVpWE_b7FoIDH4lvXLxznn--WnxV5xz4T9zyGMCTDW6Irvc84GrsIPYhlQNyIOqtg4jLBy133gYESl8ayWLSNK5zMbn0vBuHkTj4JV-6tsWAPjro-Ao9cvw1BCTadUj9B4gOH-fhtKWIa2cPBhi28Q7XaYbU4jl72kJH-OLwTtn391c3i4-z6y8fPi3m1zObq0LMbIugW6xzKOu6BK2LqihEXaZaUS8b26qyrFrIGi3qRigrSqxsqpe5apuyLrIpO9_70gaHsTFDcGsIW9ODM-_c7dz0YWXG0ci0XVEl_M0eH0J_PyJFs3ZpHV0HHvuRTFlJoYu8TOCrAzg2a1wefR_DScDrAwBkoWtTGNbRkVNSaV2lqKfscs_Z0BMFbI11EXaRpfxclwYzuzMx6UzMw5kkxdu_FMfm_2AP7hvX4fb_oJl_u9kr_gCGwdBf |
CODEN | ARHEAW |
CitedBy_id | crossref_primary_10_1002_JLB_6RI0319_094R crossref_primary_10_1016_j_autrev_2012_09_003 crossref_primary_10_1038_cddis_2016_361 crossref_primary_10_3389_fimmu_2024_1370254 crossref_primary_10_1098_rstb_2016_0355 crossref_primary_10_1073_pnas_1401505111 crossref_primary_10_1016_j_smim_2009_10_005 crossref_primary_10_1073_pnas_0904726106 crossref_primary_10_1002_art_37804 crossref_primary_10_1016_j_clim_2024_110194 crossref_primary_10_1016_j_jneuroim_2014_12_003 crossref_primary_10_1038_gene_2009_39 crossref_primary_10_3390_cells11111767 crossref_primary_10_1016_j_clim_2024_110310 crossref_primary_10_1016_j_freeradbiomed_2022_01_017 crossref_primary_10_1074_jbc_M114_608125 crossref_primary_10_1016_j_jneuroim_2015_04_005 crossref_primary_10_3390_cells13242077 crossref_primary_10_1136_annrheumdis_2012_201851 crossref_primary_10_1136_annrheumdis_2012_202742 crossref_primary_10_1136_ard_2010_138057 crossref_primary_10_2217_ijr_13_58 crossref_primary_10_1186_ar4167 crossref_primary_10_1080_15513815_2017_1367871 crossref_primary_10_1186_ar3433 crossref_primary_10_1016_j_imlet_2023_07_006 crossref_primary_10_1155_2014_203435 crossref_primary_10_1007_s12016_009_8174_6 crossref_primary_10_1016_j_semnephrol_2010_01_007 crossref_primary_10_3390_biom11091378 crossref_primary_10_1016_j_jpedsurg_2013_07_011 crossref_primary_10_1136_ard_2009_122903 crossref_primary_10_1007_s00401_014_1321_z crossref_primary_10_1016_j_jaut_2012_12_012 crossref_primary_10_3389_fmed_2022_1044856 crossref_primary_10_1016_j_nbd_2015_05_005 crossref_primary_10_1038_s41598_021_90517_8 crossref_primary_10_1016_j_jaut_2011_11_008 crossref_primary_10_3390_biom10030494 crossref_primary_10_1007_s00281_014_0440_x crossref_primary_10_1007_s11926_017_0657_5 crossref_primary_10_1093_hmg_ddu429 crossref_primary_10_3109_08916930903374865 crossref_primary_10_1186_ar2698 crossref_primary_10_1136_annrheumdis_2018_213022 crossref_primary_10_1155_2012_798924 crossref_primary_10_1155_2012_849684 crossref_primary_10_1126_scisignal_2004824 crossref_primary_10_1177_0961203313497119 crossref_primary_10_1586_eci_10_8 crossref_primary_10_3389_fimmu_2022_953439 crossref_primary_10_1177_0961203313496340 crossref_primary_10_1155_2015_421624 crossref_primary_10_1038_mp_2010_21 crossref_primary_10_1016_j_jaut_2009_12_006 crossref_primary_10_1155_2019_1703842 crossref_primary_10_1016_j_jaut_2016_08_001 crossref_primary_10_1189_jlb_0212095 crossref_primary_10_5114_reum_2019_89517 crossref_primary_10_1016_j_jaut_2017_10_004 crossref_primary_10_1038_cr_2013_110 crossref_primary_10_3390_diseases2010045 crossref_primary_10_1002_art_30563 crossref_primary_10_1016_j_abb_2024_110046 crossref_primary_10_3345_cep_2020_00633 crossref_primary_10_1016_j_jaut_2013_04_003 crossref_primary_10_1038_ncomms10836 crossref_primary_10_1097_BOR_0000000000000398 crossref_primary_10_1016_j_rdc_2014_04_002 crossref_primary_10_1002_art_30604 crossref_primary_10_1007_s10753_015_0201_6 crossref_primary_10_1016_j_clim_2014_10_007 crossref_primary_10_1016_j_trsl_2014_10_002 crossref_primary_10_1016_j_ydbio_2016_06_017 |
Cites_doi | 10.1038/ng1847 10.1073/pnas.0701953104 10.1093/bioinformatics/btg421 10.1016/S0092-8674(00)00169-0 10.1111/j.1600-0463.2008.00773.x 10.1038/sj.onc.1209684 10.1038/561 10.1093/nar/gkh349 10.1080/08916930802024202 10.1038/ng1327 10.1182/blood.V99.12.4503 10.1101/gr.077115.108 10.1080/08916930802024145 10.4049/jimmunol.154.6.3025 10.1002/art.21031 10.1038/gene.2008.29 10.1371/journal.pone.0001727 10.1002/art.1780350608 10.1093/jnci/dji204 10.1002/art.1780400928 10.1002/art.1780290608 10.1093/bioinformatics/19.2.204 10.1093/rheumatology/kei244 10.1158/1541-7786.MCR-06-0372 10.3109/08916939308993324 10.1038/nature06664 10.1126/science.1153252 10.1038/30764 10.1186/1471-2105-5-145 10.1093/bioinformatics/bth457 10.1073/pnas.87.5.1663 10.1016/j.neuron.2006.01.014 10.1084/jem.20021553 10.1002/art.10234 10.4049/jimmunol.179.8.5553 10.1093/bioinformatics/btg390 10.1097/01.bor.0000135452.62800.8f 10.1002/art.20255 10.2174/1570160053174983 10.1073/pnas.0337679100 10.1002/eji.200636872 10.4049/jimmunol.179.9.6352 |
ContentType | Journal Article |
Copyright | Copyright © 2009 by the American College of Rheumatology 2009 INIST-CNRS |
Copyright_xml | – notice: Copyright © 2009 by the American College of Rheumatology – notice: 2009 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 ADTPV AOWAS DF2 |
DOI | 10.1002/art.24360 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic SwePub SwePub Articles SWEPUB Uppsala universitet |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1529-0131 |
EndPage | 1084 |
ExternalDocumentID | oai_DiVA_org_uu_102307 19333917 21299701 10_1002_art_24360 ART24360 |
Genre | article Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: Kirkland Scholar award – fundername: University of Oklahoma College of Medicine – fundername: Lupus Foundation for Research funderid: 4303; 4302 – fundername: US Department of Veterans Affairs – fundername: National Institute of Allergy and Infectious Diseases funderid: R03‐AI‐076729 – fundername: Alliance for Lupus Research – fundername: Arthritis National Research Foundation – fundername: Oklahoma Center for the Advancement of Science and Technology (Oklahoma Applied Research) funderid: AR061‐015; AR081‐006 – fundername: NIH (National Center for Research Resources) funderid: P20‐RR‐015577; P20‐RR‐015577; R03‐AI‐076729; P01‐AR‐049084; P20‐RR‐015577; AR‐043274; AI‐063274; R01‐AR‐042460; R37‐AI‐024717; R01‐AI‐031584; R37‐AR‐062277; AR‐048940; P20‐RR‐016478; P20‐RR‐020143; P20‐RR‐15577; U19‐AI‐062629 – fundername: NCRR NIH HHS grantid: P20-RR-020143 – fundername: NCRR NIH HHS grantid: P20 RR016478 – fundername: NIAID NIH HHS grantid: R03-AI-076729 – fundername: NIAMS NIH HHS grantid: R21 AR081006 – fundername: NCRR NIH HHS grantid: UL1 RR025741 – fundername: NIAMS NIH HHS grantid: R37-AR-062277 – fundername: NIAMS NIH HHS grantid: P30 AR053483 – fundername: NIAID NIH HHS grantid: R37-AI-024717 – fundername: NIAMS NIH HHS grantid: R01 AR042460 – fundername: NIAMS NIH HHS grantid: P01-AR-049084 |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 10A 1CY 1KJ 1L6 1OB 1OC 1ZS 23N 24P 31~ 33P 3O- 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52W 52X 53G 5GY 5RE 66C 6J9 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEVG AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAQQT AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFO ACMXC ACPOU ACRPL ACSCC ACXBN ACXQS ACYXJ ADBTR ADEOM ADIZJ ADMGS ADNMO ADOZA ADZCM ADZOD AEEZP AEIGN AEIMD AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AI. AIACR AITYG AIURR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZFZN BDRZF BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM EBS EJD EMOBN EX3 F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J5H JPC KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES M65 MEWTI MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NNB OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q11 QB0 QRW RGB RIWAO RJQFR ROL RWI RX1 RXW RYL SAMSI SJN SUPJJ SV3 TAE TEORI TWZ UB1 V2E V8K V9Y VH1 W8V WH7 WIB WIH WIJ WIK WIN WJL WOW WQJ WRC WUP WXI WXSBR X6Y X7M XG1 XPP XV2 YFH YOC ZGI ZXP ZZTAW ~IA ~WT AAFWJ AAYXX AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY IQODW CGR CUY CVF ECM EIF NPM 7X8 ADTPV AOWAS DF2 |
ID | FETCH-LOGICAL-c4250-cfea9fe84a6886a99575508625058dbcf2667fa3b908b02c06e7c086642fb6853 |
IEDL.DBID | DR2 |
ISSN | 0004-3591 1529-0131 |
IngestDate | Thu Aug 21 06:47:17 EDT 2025 Fri Jul 11 04:33:47 EDT 2025 Mon Jul 21 05:29:19 EDT 2025 Mon Jul 21 09:14:53 EDT 2025 Thu Apr 24 23:07:53 EDT 2025 Tue Jul 01 01:05:06 EDT 2025 Wed Jan 22 17:04:56 EST 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Issue | 4 |
Keywords | Human Immunopathology Connective tissue disease Skin disease Systemic lupus erythematosus Transcription Systemic disease Rheumatology Autoimmune disease Gene expression |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4250-cfea9fe84a6886a99575508625058dbcf2667fa3b908b02c06e7c086642fb6853 |
Notes | MECP2 Dr. Sawalha has applied for a provisional US patent for the genetic association between and systemic lupus erythematosus. Dr. Harley has received consulting fees, speaking fees, and/or honoraria from Therapeutics Inc., Rheumatology Associates CE, S&R Communications Group, Inc., The Scientist LLC, Hudson Medical Communications, A&R Educational Group LLC, Courtesy Associates, National Jewish Medical and Research Center, American Cancer Society, BioSymposia, Scientific Conferences Group, the 8th International Congress on Systemic Lupus Erythematosus, Northwestern University, University of Texas, Johns Hopkins University, Georgetown University, and University of California (less than $10,000 each) and from Bio‐Rad Laboratories, ImmunoVision Technologies, and IVAX Diagnostics (more than $10,000 each). ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | http://doi.org/10.1002/art.24360 |
PMID | 19333917 |
PQID | 67109546 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | swepub_primary_oai_DiVA_org_uu_102307 proquest_miscellaneous_67109546 pubmed_primary_19333917 pascalfrancis_primary_21299701 crossref_citationtrail_10_1002_art_24360 crossref_primary_10_1002_art_24360 wiley_primary_10_1002_art_24360_ART24360 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | April 2009 |
PublicationDateYYYYMMDD | 2009-04-01 |
PublicationDate_xml | – month: 04 year: 2009 text: April 2009 |
PublicationDecade | 2000 |
PublicationPlace | Hoboken |
PublicationPlace_xml | – name: Hoboken – name: Hoboken , NJ – name: United States |
PublicationTitle | Arthritis and rheumatism |
PublicationTitleAlternate | Arthritis Rheum |
PublicationYear | 2009 |
Publisher | Wiley Subscription Services, Inc., A Wiley Company Wiley |
Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley |
References | 2007; 104 2004; 20 1997; 40 2006; 38 2008; 18 2002; 99 2008; 9 2005; 21 2004; 5 1992; 35 2008; 3 2003; 19 1995; 154 2008; 320 1998; 393 2007; 37 2003; 197 2004; 32 2007; 179 1990; 87 2004; 50 1998; 19 1993; 16 2006; 45 2000; 103 2004; 16 2004; 36 2006; 49 2002; 46 2006; 25 2005; 52 2005; 97 1986; 29 2008; 116 2007; 5 2005; 3 2008; 41 2008; 452 2003; 100 e_1_2_7_5_2 e_1_2_7_4_2 e_1_2_7_3_2 e_1_2_7_2_2 e_1_2_7_9_2 e_1_2_7_8_2 e_1_2_7_6_2 e_1_2_7_19_2 e_1_2_7_18_2 e_1_2_7_17_2 e_1_2_7_16_2 e_1_2_7_15_2 e_1_2_7_14_2 e_1_2_7_40_2 e_1_2_7_13_2 e_1_2_7_41_2 e_1_2_7_12_2 e_1_2_7_42_2 e_1_2_7_11_2 e_1_2_7_43_2 e_1_2_7_10_2 e_1_2_7_26_2 e_1_2_7_27_2 e_1_2_7_28_2 e_1_2_7_29_2 Yung RL (e_1_2_7_7_2) 1995; 154 e_1_2_7_25_2 e_1_2_7_24_2 e_1_2_7_30_2 e_1_2_7_23_2 e_1_2_7_31_2 e_1_2_7_22_2 e_1_2_7_32_2 e_1_2_7_21_2 e_1_2_7_33_2 e_1_2_7_20_2 e_1_2_7_34_2 e_1_2_7_35_2 e_1_2_7_36_2 e_1_2_7_37_2 e_1_2_7_38_2 e_1_2_7_39_2 |
References_xml | – volume: 452 start-page: 103 year: 2008 end-page: 7 article-title: The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response publication-title: Nature – volume: 29 start-page: 755 year: 1986 end-page: 60 article-title: Increased proto‐oncogene expression in peripheral blood lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases publication-title: Arthritis Rheum – volume: 154 start-page: 3025 year: 1995 end-page: 35 article-title: Mechanism of drug‐induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo publication-title: J Immunol – volume: 179 start-page: 6352 year: 2007 end-page: 8 article-title: Demethylation of CD40LG on the inactive X in T cells from women with lupus publication-title: J Immunol – volume: 45 start-page: 694 year: 2006 end-page: 702 article-title: Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients publication-title: Rheumatology (Oxford) – volume: 320 start-page: 1224 year: 2008 end-page: 9 article-title: MeCP2, a key contributor to neurological disease, activates and represses transcription publication-title: Science – volume: 87 start-page: 1663 year: 1990 end-page: 7 article-title: Amplified RNA synthesized from limited quantities of heterogeneous cDNA publication-title: Proc Natl Acad Sci U S A – volume: 36 start-page: 339 year: 2004 end-page: 41 article-title: A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome publication-title: Nat Genet – volume: 100 start-page: 2610 year: 2003 end-page: 5 article-title: Interferon‐inducible gene expression signature in peripheral blood cells of patients with severe lupus publication-title: Proc Natl Acad Sci U S A – volume: 32 start-page: 1818 year: 2004 end-page: 23 article-title: The major form of MeCP2 has a novel N‐terminus generated by alternative splicing publication-title: Nucleic Acids Res – volume: 37 start-page: 1407 year: 2007 end-page: 13 article-title: Defective DNA methylation and CD70 overexpression in CD4 T cells in MRL/lpr lupus‐prone mice publication-title: Eur J Immunol – volume: 103 start-page: 667 year: 2000 end-page: 78 article-title: Ordered recruitment of chromatin modifying and general transcription factors to the IFN‐β promoter publication-title: Cell – volume: 97 start-page: 1124 year: 2005 end-page: 32 article-title: Detection in fecal DNA of colon cancer‐specific methylation of the nonexpressed vimentin gene publication-title: J Natl Cancer Inst – volume: 179 start-page: 5553 year: 2007 end-page: 63 article-title: Impaired T cell protein kinase Cδ activation decreases ERK pathway signaling in idiopathic and hydralazine‐induced lupus publication-title: J Immunol – volume: 393 start-page: 386 year: 1998 end-page: 9 article-title: Transcriptional repression by the methyl‐CpG‐binding protein MeCP2 involves a histone deacetylase complex publication-title: Nature – volume: 41 start-page: 245 year: 2008 end-page: 52 article-title: Epigenetics and T‐cell immunity publication-title: Autoimmunity – volume: 40 start-page: 1725 year: 1997 article-title: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus publication-title: Arthritis Rheum – volume: 18 start-page: 1270 year: 2008 end-page: 81 article-title: Comparative analysis of human chromosome 7q21 and mouse proximal chromosome 6 reveals a placental‐specific imprinted gene, TFPI2/Tfpi2, which requires EHMT2 and EED for allelic‐silencing publication-title: Genome Res – volume: 9 start-page: 368 year: 2008 end-page: 78 article-title: Defective T‐cell ERK signaling induces interferon‐regulated gene expression and overexpression of methylation‐sensitive genes similar to lupus patients publication-title: Genes Immun – volume: 21 start-page: 263 year: 2005 end-page: 5 article-title: Haploview: analysis and visualization of LD and haplotype maps publication-title: Bioinformatics – volume: 3 start-page: 73 year: 2005 end-page: 8 article-title: DNA methylation in the pathogenesis of systemic lupus erythematosus publication-title: Curr Pharmacogenomics – volume: 19 start-page: 187 year: 1998 end-page: 91 article-title: Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription publication-title: Nat Genet – volume: 25 start-page: 6948 year: 2006 end-page: 58 article-title: Dual role of TMS1/ASC in death receptor signaling publication-title: Oncogene – volume: 38 start-page: 904 year: 2006 end-page: 9 article-title: Principal components analysis corrects for stratification in genome‐wide association studies publication-title: Nat Genet – volume: 16 start-page: 534 year: 2004 end-page: 40 article-title: Antinuclear autoantibodies in systemic lupus erythematosus publication-title: Curr Opin Rheumatol – volume: 20 start-page: 389 year: 2004 end-page: 98 article-title: Knowledge discovery by automated identification and ranking of implicit relationships publication-title: Bioinformatics – volume: 104 start-page: 13028 year: 2007 end-page: 33 article-title: Cellular senescence is an important mechanism of tumor regression upon c‐Myc inactivation publication-title: Proc Natl Acad Sci U S A – volume: 99 start-page: 4503 year: 2002 end-page: 8 article-title: Effect of DNA methylation and chromatin structure on ITGAL expression publication-title: Blood – volume: 5 start-page: 145 year: 2004 article-title: Extending the mutual information measure to rank inferred literature relationships publication-title: BMC Bioinformatics – volume: 116 start-page: 21 year: 2008 end-page: 6 article-title: Aberrant methylation in promoter regions of cyclin‐dependent kinase inhibitor genes in adenoid cystic carcinoma of the salivary gland publication-title: APMIS – volume: 41 start-page: 253 year: 2008 end-page: 71 article-title: ICF, an immunodeficiency syndrome: DNA methyltransferase 3B involvement, chromosome anomalies, and gene dysregulation publication-title: Autoimmunity – volume: 3 start-page: e1727 year: 2008 article-title: Common variants within MECP2 confer risk of systemic lupus erythematosus publication-title: PLoS ONE – volume: 50 start-page: 1850 year: 2004 end-page: 60 article-title: Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors publication-title: Arthritis Rheum – volume: 19 start-page: 204 year: 2003 end-page: 11 article-title: An associative analysis of gene expression array data publication-title: Bioinformatics – volume: 20 start-page: 191 year: 2004 end-page: 8 article-title: Shared relationship analysis: ranking set cohesion and commonalities within a literature‐derived relationship network publication-title: Bioinformatics – volume: 16 start-page: 167 year: 1993 end-page: 71 article-title: Expression of c‐myc, c‐myb, and c‐sis in fibroblasts from affected and unaffected skin of patients with systemic sclerosis publication-title: Autoimmunity – volume: 52 start-page: 1491 year: 2005 end-page: 503 article-title: Activation of the interferon‐α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease publication-title: Arthritis Rheum – volume: 35 start-page: 647 year: 1992 end-page: 62 article-title: Phenotypic and functional similarities between 5‐azacytidine–treated T cells and a T cell subset in patients with active systemic lupus erythematosus publication-title: Arthritis Rheum – volume: 49 start-page: 321 year: 2006 end-page: 3 article-title: The ups and downs of BDNF in Rett syndrome publication-title: Neuron – volume: 197 start-page: 711 year: 2003 end-page: 23 article-title: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood publication-title: J Exp Med – volume: 5 start-page: 1181 year: 2007 end-page: 9 article-title: Epigenetic down‐regulation of ARF expression is a selection step in immortalization of human fibroblasts by c‐Myc publication-title: Mol Cancer Res – volume: 46 start-page: 1282 year: 2002 end-page: 91 article-title: Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus publication-title: Arthritis Rheum – ident: e_1_2_7_14_2 doi: 10.1038/ng1847 – ident: e_1_2_7_38_2 doi: 10.1073/pnas.0701953104 – ident: e_1_2_7_30_2 doi: 10.1093/bioinformatics/btg421 – ident: e_1_2_7_27_2 doi: 10.1016/S0092-8674(00)00169-0 – ident: e_1_2_7_34_2 doi: 10.1111/j.1600-0463.2008.00773.x – ident: e_1_2_7_31_2 doi: 10.1038/sj.onc.1209684 – ident: e_1_2_7_10_2 doi: 10.1038/561 – ident: e_1_2_7_19_2 doi: 10.1093/nar/gkh349 – ident: e_1_2_7_41_2 doi: 10.1080/08916930802024202 – ident: e_1_2_7_18_2 doi: 10.1038/ng1327 – ident: e_1_2_7_35_2 doi: 10.1182/blood.V99.12.4503 – ident: e_1_2_7_42_2 doi: 10.1101/gr.077115.108 – ident: e_1_2_7_26_2 doi: 10.1080/08916930802024145 – volume: 154 start-page: 3025 year: 1995 ident: e_1_2_7_7_2 article-title: Mechanism of drug‐induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo publication-title: J Immunol doi: 10.4049/jimmunol.154.6.3025 – ident: e_1_2_7_25_2 doi: 10.1002/art.21031 – ident: e_1_2_7_28_2 doi: 10.1038/gene.2008.29 – ident: e_1_2_7_9_2 doi: 10.1371/journal.pone.0001727 – ident: e_1_2_7_3_2 doi: 10.1002/art.1780350608 – ident: e_1_2_7_33_2 doi: 10.1093/jnci/dji204 – ident: e_1_2_7_12_2 doi: 10.1002/art.1780400928 – ident: e_1_2_7_39_2 doi: 10.1002/art.1780290608 – ident: e_1_2_7_15_2 doi: 10.1093/bioinformatics/19.2.204 – ident: e_1_2_7_24_2 doi: 10.1093/rheumatology/kei244 – ident: e_1_2_7_37_2 doi: 10.1158/1541-7786.MCR-06-0372 – ident: e_1_2_7_40_2 doi: 10.3109/08916939308993324 – ident: e_1_2_7_32_2 doi: 10.1038/nature06664 – ident: e_1_2_7_11_2 doi: 10.1126/science.1153252 – ident: e_1_2_7_22_2 doi: 10.1038/30764 – ident: e_1_2_7_29_2 doi: 10.1186/1471-2105-5-145 – ident: e_1_2_7_13_2 doi: 10.1093/bioinformatics/bth457 – ident: e_1_2_7_17_2 doi: 10.1073/pnas.87.5.1663 – ident: e_1_2_7_43_2 doi: 10.1016/j.neuron.2006.01.014 – ident: e_1_2_7_20_2 doi: 10.1084/jem.20021553 – ident: e_1_2_7_36_2 doi: 10.1002/art.10234 – ident: e_1_2_7_5_2 doi: 10.4049/jimmunol.179.8.5553 – ident: e_1_2_7_16_2 doi: 10.1093/bioinformatics/btg390 – ident: e_1_2_7_2_2 doi: 10.1097/01.bor.0000135452.62800.8f – ident: e_1_2_7_6_2 doi: 10.1002/art.20255 – ident: e_1_2_7_4_2 doi: 10.2174/1570160053174983 – ident: e_1_2_7_21_2 doi: 10.1073/pnas.0337679100 – ident: e_1_2_7_8_2 doi: 10.1002/eji.200636872 – ident: e_1_2_7_23_2 doi: 10.4049/jimmunol.179.9.6352 |
SSID | ssj0002353 |
Score | 1.647459 |
Snippet | Objective
Both genetic and epigenetic factors play an important role in the pathogenesis of lupus. The aim of this study was to examine methyl‐CpG–binding... Both genetic and epigenetic factors play an important role in the pathogenesis of lupus. The aim of this study was to examine methyl-CpG-binding protein 2 gene... OBJECTIVE: Both genetic and epigenetic factors play an important role in the pathogenesis of lupus. The aim of this study was to examine methyl-CpG-binding... |
SourceID | swepub proquest pubmed pascalfrancis crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1076 |
SubjectTerms | B-Lymphocytes - cytology B-Lymphocytes - physiology Biological and medical sciences Cells, Cultured Cohort Studies Diseases of the osteoarticular system Epigenesis, Genetic Female Gene Frequency Genetic Predisposition to Disease - ethnology Genetic Variation Haplotypes Humans Lupus Erythematosus, Systemic - ethnology Lupus Erythematosus, Systemic - genetics Male Medical sciences MEDICIN MEDICINE Methyl-CpG-Binding Protein 2 - genetics Phenotype Polymorphism, Single Nucleotide Risk Factors Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis White People - statistics & numerical data |
Title | Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fart.24360 https://www.ncbi.nlm.nih.gov/pubmed/19333917 https://www.proquest.com/docview/67109546 https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-102307 |
Volume | 60 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9UwFA5jD0MQnb_rdAZR2IO9603btMWnMTeGcEXEjT0IIUmTcfHSXtpb2Pan-dd5TpP2cmWC-NaSNP315eQ7ycl3CHmXSsvjslShwe2_mOMqVGmRhAqzdYM5VMzi5uTZF352nny-TC-3yMdhL4zThxgn3LBn9PYaO7hU7eFaNBS-7IQlMUd_HWO1kBB9W0tHsdgrUOLMf1pMB1WhiB2OV26MRfeXsoXPYl0-i7sI56gmuklk-5Ho9CH5MbyDC0D5OelWaqJv_5B3_M-X3CUPPEOlRw5Sj8iWqR6TnZlfg39Cfl2Ae43RMxTncOcVnZ0cf2UfqKRgD-gKx77BEtHGZbqvGyhuDJUeC6bsr6XzCjlrC6dt1_bxNX2oLrRS00W37Foqq5IOOVzAFi0o4N1Qc-3DdytognppWPc81ElTz7VvwDQ3Tpe2hls8JeenJ9-Pz0KfASLUYEuiUFsjC2vyRPI85xLglIFHBU4Y8La8VNoCvcisjFUR5SpiOuIm01AOTpVVHJjIM7Jd1ZV5QajUppSJNVpqluikzLXNbMSM1Uh5mA7IwYAFob08OmbpWAgn7MwE_AvR_4uAvB2rLp0myF2V9jcANdYErlAUWTQNyJsBYQK6NK7TyMrUXSs4xsemCQ_Icwe89V2KOI7BwQ7Ie4fEsQRVwj_NL45E3VyJrhOoyBFBvYMeXX9_TAFuU3_w8t-r7pF7w5paNH1FtldNZ14DNVup_b4P_gaY7jp2 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1baxQxFD6UFlQQ75ex2gZR6IOznc3cwZdSW1btFpG29EVCkklkcZlZZnag-tP8dT1JZmZZqSC-zZBM5vbl5DvJyXcA3sRcJ2FRCF-Z7b8mx5Uv4jzyhcnWjeZQUG02J09Pk8l59OkyvtyA9_1eGKcPMUy4mZ5h7bXp4GZCen-lGoqfdkSjMEGHfctk9LYO1deVeBQNOw1KM_cf5-NeVyig-8Ola6PR3QVv8MNol9HiJso56ImuU1k7Fh3fh2_9W7gQlB-jdilG8tcfAo__-5oP4F5HUsmBQ9VD2FDlI7g17ZbhH8PvC_SwTQANMdO4s5JMjw6_0HeEEzQJZGmGv94Ykdolu69qLK4V4R0cVGGvJbPS0NYGT5u2sSE2NloXW6nIvF20DeFlQfo0LmiO5gQhr4i66iJ4S2yCdOqw7nmIU6eeya4BVf900rQV3uIJnB8fnR1O_C4JhC_RnAS-1IrnWmURT7Is4YioFJ0q9MOQumWFkBoZRqp5KPIgEwGVQaJSieXoV2mRIBl5CptlVarnQLhUBY-0klzSSEZFJnWqA6q0NKyHSg_2ejAw2Smkm0Qdc-a0nSnDf8Hsv_Dg9VB14WRBbqq0s4aooSbShTxPg7EHuz3EGPZqs1TDS1W1DUtMiGwcJR48c8hb3SUPwxB9bA_eOigOJUYo_MPs4oBV9XfWtsyIcgRYb8_C6--PydBzsgcv_r3qLtyenE1P2MnH08_bcKdfYgvGL2FzWbfqFTK1pdixHfIaAio-kQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBalgzIYu1_cba0YG_RhThXZlm32VJqG7pJSxlr6MBCSLI3QYAc7hm0_bb9uR5LtkNHB2JuNZPn26eg70tF3EHqdCMOiopChttt_bY6rUCZ5HEqbrRvMoaTGbk6enbHTi_jDVXK1hd71e2G8PsQw4WZ7hrPXtoMvC3O4Fg2FLzuiccTAX78VM5JZSE8-r7WjaNRJUNqp_yQf97JChB4Ol24MRneWooHvYnxCi5sY5yAnuslk3VA0vYe-9i_hI1CuR-1KjtTPP_Qd__Mt76O7HUXFRx5TD9CWLh-inVm3CP8I_boE_9qGz2A7iTsv8ezk-Jy-xQKDQcArO_j1pgjXPtV9VUNxrbHowKALdy2el5a0NnDatI0LsHGxutBKhRftsm2wKAvcJ3EBY7TAAHiN9fcufreEJnCnDeufB3tt6rnqGtD1Dy9MW8EtHqOL6cmX49OwSwERKjAmJFRGi9zoLBYsy5gAPKXgUoEXBsQtK6QywC9SIyKZk0wSqgjTqYJy8KqMZEBFnqDtsir1M4SF0oWIjVZC0VjFRaZMagjVRlnOQ1WADnoscNXpo9s0HQvulZ0ph3_B3b8I0Kuh6tKLgtxUaW8DUENNIAt5npJxgPZ7hHHo03ahRpS6ahvObIBsErMAPfXAW98lj6IIPOwAvfFIHEqsTPhkfnnEq_obb1tuJTkI1Dtw6Pr7Y3Lwm9zB7r9X3Uc755Mp__T-7ONzdLtfXyPjF2h7Vbf6JdC0ldxz3fE3S1M9SQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Variants+within+MECP2+%2C+a+key+transcription+regulator%2C+are+associated+with+increased+susceptibility+to+lupus+and+differential+gene+expression+in+patients+with+systemic+lupus+erythematosus&rft.jtitle=Arthritis+and+rheumatism&rft.au=Webb%2C+Ryan&rft.au=Wren%2C+Jonathan+D.&rft.au=Jeffries%2C+Matlock&rft.au=Kelly%2C+Jennifer+A.&rft.date=2009-04-01&rft.issn=0004-3591&rft.eissn=1529-0131&rft.volume=60&rft.issue=4&rft.spage=1076&rft.epage=1084&rft_id=info:doi/10.1002%2Fart.24360&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_art_24360 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0004-3591&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0004-3591&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0004-3591&client=summon |